OrganRegen Biotechnology Co., Ltd. is a 100% wholly owned subsidiary of bioGenous Biotechnology Inc., headquartered in Suzhou Industrial Park, China. bioGenous provides standardized adult or pluripotent stem cell-derived organoid culture reagents and comprehensive technical services in basic research, precision medicine, and drug discovery and development. 


bioGenous was founded by a group of scientists with years of experience and knowledge of organoid technology. Our research team successfully utilized human-derived organoids in the establishment of the first COVID-19 infection model, hepatoblastoma formation, and other disease models to fast-track new drug research and development. 


We have developed the world's first fully automated high-throughput organoid culture and drug discovery platform to aid standardized organoid culture, drug screening, and evaluation. bioGenous has developed a comprehensive range of both cancer and normal patient-derived organoid reagents covering multi-lineage and multiple cancers as well as providing contract development and manufacturing organization (CDMO) and contract research organization (CRO) services.


Our vision is to become a global player in organoid technology by sharing knowledge on organoid technology and providing organoid-based models to spearhead preclinical studies, medical innovations, basic research, and high-throughput and efficient drug discovery and screening platforms.